Dabrafenib,Trametinib,Pembrolizumab
novartis,merck
['melanoma']
toxicity rate continues to be really challenging. lots of patient discontinuations in the concurrent arm. #melanoma #asco22 
Melanoma+Cell Therapy Oncologist @MSKCancerCenter| Cornell/DukeMed/ MGH IM/MSKCC Onc alum | FCOI: https://t.co/kwtet64Pe4